CHEMED CORP
10-Q, 1997-05-12
CHEMICALS & ALLIED PRODUCTS
Previous: CENTRAL POWER & LIGHT CO /TX/, 424B5, 1997-05-12
Next: BELL ATLANTIC WASHINGTON DC INC, 10-Q, 1997-05-12



- -------------------------------------------------------------------
- -------------------------------------------------------------------
                                   FORM 10-Q
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                  Quarterly Report Under Section 13 or 15 (d)
                    of the Securities Exchange Act of 1934

For Quarter Ended March 31, 1997

Commission File Number 1-8351

                              CHEMED CORPORATION
            (Exact name of registrant as specified in its charter)


            Delaware                          31-0791746      
(State or other jurisdiction of   (IRS Employer Identification No.)
 incorporation or organization)


2600 Chemed Center, 255 E. Fifth Street, Cincinnati, Ohio 45202  

(Address of principal executive offices)              (Zip code)


                                (513) 762-6900
             (Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports) and (2) has been subject to such filing requirements
for the past 90 days.         Yes  X            No     
                                  ----             ----

Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.


Class                   Amount                        Date

Capital Stock           10,032,599 Shares             April 30, 1997
$1 Par Value      
- ------------------------------------------------------------------
- ------------------------------------------------------------------



                                 Page 1 of 12<PAGE>

                            CHEMED CORPORATION AND 
                             SUBSIDIARY COMPANIES



                                     Index
<TABLE>
<CAPTION>
                                                                Page No.
<S>                                                             <C>
PART I.    FINANCIAL INFORMATION:

  Item 1.  Financial Statements
        Consolidated Balance Sheet -
          March 31, 1997 and
          December 31, 1996                                             3

        Consolidated Statement of Income -
          Three months ended
          March 31, 1997 and 1996                                       4

        Consolidated Statement of Cash Flows -              
          Three months ended
          March 31, 1997 and 1996                                       5

        Notes to Unaudited Financial Statements                         6


  Item 2.  Management's Discussion and Analysis of                          
             Financial Condition and Results of 
              Operations                                           7 - 10

PART II.   OTHER INFORMATION                                           11
</TABLE>
















                                 Page 2 of 12<PAGE>
                               PART I. FINANCIAL INFORMATION
                               Item 1. Financial Statements
                        CHEMED CORPORATION AND SUBSIDIARY COMPANIES
                                CONSOLIDATED BALANCE SHEET
                      (in thousands except share and per share data)
                                         UNAUDITED
<TABLE>
<CAPTION>
                                                                   March 31,    December 31,
                                                                     1997          1996  
                                                                  ----------    ----------
<S>                                                               <C>          <C>
ASSETS
Current assets
   Cash and cash equivalents                                      $   17,797   $   11,935
   Accounts receivable, less allowances of $2,971 
      (1996 - $2,925)                                                 79,719       77,622
   Inventories
      Raw materials                                                    6,615        6,515
      Finished goods and general merchandise                          44,814       45,873
   Statutory deposits                                                 18,133       19,962
   Other current assets                                               32,234       30,452
                                                                  ----------   ----------
        Total current assets                                         199,312      192,359
Other investments                                                     44,793       62,098
Properties and equipment, at cost less accumulated
   depreciation of $59,360 (1996 - $56,653)                           84,184       83,259
Identifiable intangible assets less accumulated 
   amortization of $4,256 (1996 - $3,977)                             17,016       17,295
Goodwill less accumulated amortization of $26,672 
   (1996 - $25,292)                                                  185,847      186,933
Other assets                                                          17,483       17,406
                                                                  ----------   ----------
        Total Assets                                              $  548,635   $  559,350
                                                                  ==========   ==========
LIABILITIES
Current liabilities
   Accounts payable                                               $   25,575   $   25,747
   Bank notes and loans payable                                        5,000        5,000
   Current portion of long-term debt                                  13,074       12,550
   Income taxes                                                        9,787        5,209
   Deferred contract revenue                                          25,184       24,735
   Other current liabilities                                          45,309       51,307
                                                                  ----------   ----------
        Total current liabilities                                    123,929      124,548
Deferred income taxes                                                  2,358        6,650
Long-term debt                                                       158,092      158,168
Other liabilities and deferred income                                 40,105       41,273
Minority interest                                                     11,215       10,820
                                                                  ----------   ----------
        Total Liabilities                                            335,699      341,459
                                                                  ----------   ----------
STOCKHOLDERS' EQUITY
Capital stock-authorized 15,000,000 shares $1 par;
   issued 12,858,264 shares (1996 - 12,767,565 shares)                12,858       12,768
Paid-in capital                                                      153,785      150,296
Retained earnings                                                    142,583      139,262
Treasury stock - 2,825,975 shares 
  (1996 - 2,815,655 shares), at cost                                 (83,314)     (82,943)
Unearned compensation                                                (28,656)     (27,554)
Unrealized appreciation on investments                                15,680       26,062
                                                                  ----------   ----------
        Total Stockholders' Equity                                   212,936      217,891
                                                                  ----------   ----------
        Total Liabilities and Stockholders' Equity                $  548,635   $  559,350
                                                                  ==========   ==========

                 See accompanying notes to unaudited financial statements.
</TABLE>      
                                    Page 3 of 12<PAGE>

                        CHEMED CORPORATION AND SUBSIDIARY COMPANIES
                             CONSOLIDATED STATEMENT OF INCOME
                                         UNAUDITED
                           (in thousands except per share data)
<TABLE>
<CAPTION>
                                                                    Three Months Ended
                                                                         March 31,
                                                                  ----------------------
                                                                     1997         1996
                                                                  ---------    ---------
<S>                                                               <C>          <C>
Sales                                                             $ 94,932     $ 99,763
Service revenues                                                    73,620       67,698
                                                                  ---------    ---------
      Total sales and service revenues                             168,552      167,461
                                                                  ---------    ---------
Cost of goods sold                                                  64,311       68,590
Cost of services provided                                           45,104       41,113
Selling and marketing expenses                                      24,698       24,258
General and administrative expenses                                 24,037       23,516
Depreciation                                                         3,947        2,973
                                                                  ---------    ---------
      Total costs and expenses                                     162,097      160,450
                                                                  ---------    ---------
Income from operations                                               6,455        7,011
Interest expense                                                    (2,756)      (1,931)
Other income - net                                                  10,227       16,298
                                                                  ---------    ---------
Income before income taxes 
   and minority interest                                            13,926       21,378
Income taxes                                                        (5,333)      (7,974)
Minority interest in earnings of subsidiaries                         (106)      (1,207)
                                                                  ---------    ---------
      Net Income                                                  $  8,487     $ 12,197
                                                                  =========    =========

Earnings Per Common Share
      Net income                                                  $    .85     $   1.24
                                                                  =========    =========
      Average number of shares outstanding                          10,002        9,867
                                                                  =========    =========
Cash Dividends Paid Per Share                                     $    .52     $    .52
                                                                  =========    =========




                 See accompanying notes to unaudited financial statements.
</TABLE>




                                       Page 4 of 12<PAGE>
                        CHEMED CORPORATION AND SUBSIDIARY COMPANIES
                           CONSOLIDATED STATEMENT OF CASH FLOWS
                                         UNAUDITED
                                      (in thousands)
<TABLE>
<CAPTION>
                                                                    Three Months Ended
                                                                         March 31,
                                                                  -----------------------
                                                                     1997         1996
                                                                  ---------    ---------
<S>                                                              <C>           <C>
Cash Flows From Operating Activities     
      Net income                                                  $   8,487    $12,197
      Adjustments to reconcile net income to net cash
        provided by operating activities:
              Gain on sale of investments                            (9,079)   (14,208)  
              Depreciation and amortization                           5,927      4,611
              Provision for deferred income taxes                       202     (2,631)   
              Provision for uncollectible accounts receivable           183        459   
              Minority interest in earnings of subsidiaries             106      1,207 
              Changes in operating assets and liabilities,
                excluding amounts acquired in business
                combinations 
                 (Increase)/decrease in accounts
                    receivable                                       (2,105)     4,960   
                 Decrease in inventories and other current
                   assets                                               215      2,789     
                 (Increase)/decrease in statutory deposits            1,829       (191) 
                 Decrease in accounts payable, deferred
                   contract revenue and other current 
                   liabilities                                       (2,483)    (5,307)  
                  Increase in income taxes                            5,010     11,001
              Other - net                                            (1,693)    (2,771)  
                                                                  ---------    ---------
        Net cash provided by operating activities                     6,599     12,116   
                                                                  ---------    ---------
Cash Flows From Investing Activities
      Proceeds from sale of investments                              10,474     26,556   
      Capital expenditures                                           (4,424)    (4,177)  
      Business combinations, net of cash acquired                    (3,674)    (2,198)
      Net cash outflow from discontinued operations                    (661)    (4,294) 
      Other - net                                                       105        252     
                                                                  ---------    ---------
        Net cash provided/(used) by investing activities              1,820     16,139  
                                                                  ---------    ---------
Cash Flows From Financing Activities
      Proceeds from issuance of long-term debt                       25,000          -
      Repayment of long-term debt                                   (23,066)       (64)  
      Dividends paid                                                 (5,217)    (5,137)  
      Issuance of capital stock                                          55        165     
      Purchase of treasury stock                                          -       (870)  
      Other - net                                                       671        429 
                                                                  ---------    ---------
        Net cash used by financing activities                        (2,557)    (5,477)  
                                                                  ---------    ---------
Increase In Cash And Cash Equivalents                                 5,862     22,778  
Cash and cash equivalents at beginning of period                     11,935     19,187 
                                                                  ---------    ---------
Cash and cash equivalents at end of period                        $  17,797    $41,965
                                                                  =========    =========


                 See accompanying notes to unaudited financial statements.
</TABLE>

                                       Page 5 of 12<PAGE>
                  CHEMED CORPORATION AND SUBSIDIARY COMPANIES
                     
                    Notes to Unaudited Financial Statements


1.  The accompanying unaudited consolidated financial statements
    have been prepared in accordance with Rule 10-01 of SEC
    Regulation S-X.  Consequently, they do not include all the
    disclosures required under generally accepted accounting
    principles for complete financial statements.  However, in
    the opinion of the management of Chemed Corporation (the
    "Company"), the financial statements presented herein contain
    all adjustments, consisting only of normal recurring
    adjustments, necessary to present fairly the financial
    position, results of operations and cash flows of the Company
    and its consolidated subsidiaries ("Chemed").  For further
    information regarding Chemed's accounting policies, refer to
    the consolidated financial statements and notes included in
    Chemed's Annual Report on Form 10-K for the year ended
    December 31, 1996.

2.  Primary earnings per common share are computed using the
    weighted average number of shares of capital stock
    outstanding and exclude the dilutive effect of outstanding
    stock options as it is not material.  

    In February 1997, the Financial Accounting Standards
    Board issued Statement of Financial Accounting Standards
    No. 128 ("SFAS 128"), Earnings Per Share, effective for
    reporting periods ending after December 15, 1997. 
    Adoption of SFAS 128 in December 1997 is not expected to
    impact the Company's reported earnings per share.

3.  In March 1997, the Company borrowed $25 million under a long
    term note agreement ("Senior Notes") with New York Life
    Insurance Company and New York Life Insurance and Annuity
    Corporation.  The Senior Notes bear interest at 7.31% per
    annum, payable on March 15 and September 15 of each year. 
    Principal payments of $5,000,000 are due annually on March
    15, 2005 through 2009.  The proceeds of the Senior Notes were
    used to reduce borrowings under the Company's revolving
    credit agreement with Bank of America.










                                 Page 6 of 12<PAGE>
                 Item 2. Management's Discussion and Analysis
               of Financial Condition and Results of Operations

Financial Condition
- -------------------

            Cash and cash equivalents increased from $11.9 million
at December 31, 1996 to $17.8 million at March 31, 1997,
primarily due to the sale of investments during the first quarter
of 1997.  Other investments declined from $62.1 million at
December 31, 1996 to $44.8 million at March 31, 1997 due to the
sale of investments ($10.5 million) and to a decline in market
prices of investments owned during the quarter ($6.8 million).
   
            Income taxes increased from $5.2 million at December
31, 1996 to $9.8 million at March 31, 1997 due to the accrual of
income taxes on first quarter income and the lack of required
federal tax payments in 1997.  Other current liabilities declined
from $51.3 million at December 31, 1996 to $45.3 million due to
the payment in February 1997 of 1996 incentive compensation and
to the payment in March 1997 of a contingent payment related to
the 1994 acquisition of Patient Care.

            Vitas Healthcare Corporation, ("Vitas"), the privately-
held provider of hospice services to the terminally ill in which
the Company carries an investment of $27 million of redeemable
preferred stock, is continuing to explore long-term financing
alternatives to increase its liquidity.  On the basis of current
information, management believes the Company's investment in
Vitas is fully recoverable and that no permanent impairment
exits.

            At March 31, 1997 Chemed had approximately $50.3
million of unused lines of credit with various banks.  Management
believes its liquidity and sources of capital are satisfactory
for the Company's needs in the foreseeable future.













                                 Page 7 of 12<PAGE>
Results of Operations
- ---------------------

            Sales and service revenues and operating profit from
continuing operations by business segment follow (in thousands):
<TABLE>
<CAPTION>
                                      Three Months Ended
                                           March 31,       
                                      -------------------
                                        1997        1996 
                                      -------     --------  
Sales and Service
     Revenues    
- -----------------
<S>                                   <C>         <C>
Roto-Rooter                           $ 51,724    $ 47,783 
National Sanitary Supply                74,349      77,277 
Patient Care                            25,933      23,890 
Omnia Group                             16,546      18,511 
                                      --------     -------
  Total                               $168,552    $167,461 
                                      ========    ========

Operating Profit
- ----------------
Roto-Rooter                           $  4,461    $  4,199 
National Sanitary Supply                 1,434       1,884 
Patient Care                               985       1,073 
Omnia Group                                688       1,493 
                                      --------    --------
  Total                               $  7,568    $  8,649 
                                      ========    ========
</TABLE>
Data relating to (a) the increase or decrease in sales and
service revenues and (b) operating profit as a percent of sales
and service revenues are set forth below:
<TABLE>
<CAPTION>
                                 Sales and             Operating 
                              Service Revenues        Profit as a
                                % Increase/            % of Sales
                                 (Decrease)           (Operating Margin)
                              ----------------        ---------------
                               1997 vs. 1996          1997      1996
                              ----------------        ---------------

<S>                                     <C>            <C>       <C>
Roto-Rooter                             8 %            8.6%      8.8%
National Sanitary Supply               (4)             1.9       2.4
Patient Care                            9              3.8       4.5
Omnia Group                           (11)             4.2       8.1
    Total                               1              4.5       5.2
</TABLE>
                                 Page 8 of 12<PAGE>
            Sales and service revenues for the Roto-Rooter segment
for the first quarter of 1997 totalled $51,724,000, an increase
of 8% over the $47,783,000 recorded in the first quarter of 1996. 
Revenues of the plumbing services business, the drain cleaning
business and the service contract business increased 10%, 6% and
7%, respectively, for the first quarter of 1997, as compared with
revenues recorded in the first quarter of 1996.  These revenues
accounted for 26%, 32% and 31%, respectively, of Roto-Rooter's
total sales and service revenues during the 1997 period.  The
operating margin of the Roto-Rooter segment in the first quarter
of 1997 was 8.6% as compared with 8.8% during the first quarter
of 1996.  This decline was attributable to the additional
goodwill amortization recorded in the 1997 period due to the
purchase of Roto-Rooter's minority interest by Chemed in
September 1996.  Excluding this additional amortization the
operating margin for the first quarter of 1997 would have been
9.4%, reflecting lower general administrative expenses as a
percent of sales during the 1997 period.

            Sales of the National Sanitary Supply segment for the
first quarter of 1997 totalled $74,349,000 as compared with
$77,277,000 in the prior year first quarter.  Also, the operating
margin for the first quarter of 1997 was 1.9% as compared with
2.4% during the comparable period of 1996.  These declines were
due to the loss in the first quarter of 1996 of a large fast-food
customer, as well as deflationary pricing in National Sanitary
Supply's paper line.  The loss of this customer will no longer
impact revenue comparisons beginning in the second quarter of
1997.

            Total revenues of the Patient Care segment increased 9%
from $23,890,000 during the first quarter of 1996 to $25,933,000
in the first quarter of 1997.  This revenue increase is
attributable to increased business referrals as well as to
growing demand for home-based health care services.  The
operating margin declined from 4.5% during the first quarter of
1996 to 3.8% during the first quarter of 1997, largely as a
result of a lower gross margin percentage during the 1997
quarter.  This lower gross margin reflects lower reimbursement
rates, particularly in the New York market.  Patient Care is
aggressively increasing training classes for new home-health care
aides in order to lower its overall cost of labor and to improve
its margin.  Partially offsetting this gross margin decline were
lower general and administrative expenses as a percent of sales
during the 1997 quarter.  







                                 Page 9 of 12<PAGE>
            Sales of the Omnia segment declined 11% in the first
quarter of 1997, from $18,511,000 in the first quarter of 1996 to
$16,546,000 in the first quarter of 1997.  Also, the operating
margin of the Omnia segment declined from 8.1% during the first
quarter of 1996 to 4.2% during the comparable period of 1997. 
These declines were due primarily to lower paper-product selling
prices in 1997 as compared with the first quarter of 1996.  In
addition, operating expenses increased in 1997, due to favorable
expense reductions recorded in the first quarter of 1996. 
Significantly, Omnia has maintained its market share, and the
gross margin in the first quarter of 1997 increased when compared
with the gross margin for the last quarter of 1996.

            Income from operations declined from $7,011,000 in the
first three months in 1996 to $6,455,000 during the first three
months of 1997, largely as a result of lower operating profit in
the National Sanitary Supply and Omnia Group segments, offset
partially by favorable reductions in corporate expenses. 
Interest expense for the first quarter increased from $1,931,000
during 1996 to $2,756,000 during 1997, largely due to the
increase in total debt resulting from Chemed's purchase of the
Roto-Rooter minority interest in September 1996.

            Other income--net decreased from $16,298,000 in the
first quarter of 1996 to $10,227,000 in the first quarter of
1997, primarily as a result of lower investment gains recorded in
the 1997 period.  During the first quarter of 1997 the Company
recorded gains on the sales of investments aggregating $9,079,000
as compared with $14,208,000 during the first quarter of 1996. 
Lower interest income for the 1997 period as compared with the
1996 first quarter also contributed to this decline.  

            The Company's effective income tax rate during the
first quarter of 1997 was 38.3% as compared with 37.3% during the
first three months of 1996.  This increase was attributable to a
higher effective state and local income tax rate during the 1997
period.  
            Net income declined from $12,197,000 ($1.24 per share)
in the 1996 first quarter to $8,487,000 ($.85 per share) in the
1997 first quarter, largely as a result of lower investment gains
and lower income from operations recorded in the 1997 quarter. 
Excluding investment gains for both periods, net income declined
from $3,273,000 ($.33 per share) for the 1996 quarter to
$2,861,000 ($.29 per share) during the 1997 quarter.








                                 Page 10 of 12<PAGE>
                         PART II -- OTHER INFORMATION
                         ----------------------------

Item 6.   Exhibits and Reports on Form 8-K

    (a)   Exhibits
          --------
<TABLE>
<CAPTION>
          Exhibit        SK 601                                 Page
            No.         Ref. No.      Description               No. 
          -------       --------      ------------------        ----------
            <C>           <C>         <S>                       <C>
            1             (11)        Statement re:             
                                      Computation of Per
                                      Share Earnings            E-1

            2             (27)        Financial Data 
                                      Schedule                  E-2 and E-3

    (b)   Reports on Form 8-K - None
          --------------------------
</TABLE>
                                  SIGNATURES

        Pursuant to the requirements of the Securities Exchange
        Act of 1934, the Registrant has duly caused this report to
        be signed on its behalf by the undersigned thereunto duly
        authorized.


                                           Chemed Corporation     
                                          -------------------------
                                             (Registrant)


Dated:  May 12, 1997                  By   Naomi C. Dallob
        ----------------------           -------------------------
                                           Naomi C. Dallob, Vice
                                           President and Secretary




Dated:  May 12, 1997                  By   Arthur V. Tucker, Jr.
        ----------------------           -------------------------
                                           Arthur V. Tucker, Jr.
                                           Vice President and
                                           Controller (Principal
                                           Accounting Officer)


                                 Page 11 of 12<PAGE>


           CHEMED CORPORATION AND SUBSIDIARY COMPANIES
                COMPUTATION OF PER SHARE EARNINGS
              (in thousands except per share data)     EXHIBIT 11
<TABLE>
<CAPTION>

                                                           Net Income
                                                       ------------------
                                                        Three Months Ended
                                                            March 31,
                                                       -------------------
                                                         1997      1996
                                                       -------------------
Computation of Earnings Per Common
<F1>
  and Common Equivalent Share (a):    
- ----------------------------------
<S>                                                    <C>       <C>
Reported Income                                        $ 8,487   $12,197
                                                       =======   =======

Average number of shares used to
  compute earnings per common share                     10,002     9,867  

Effect of unexercised stock options                         39        70
                                                       -------   -------
Average number of shares used to
  compute earnings per common 
  and common equivalent share                           10,041     9,937
                                                       =======   =======
Earnings per common and
  common equivalent share                              $   .85   $  1.23
                                                       =======   =======

Computation of Earnings Per
  Common Share Assuming
<F1>
  Full Dilution (a):       
- ---------------------------
Reported Income                                        $ 8,487   $12,197
                                                       =======   =======
Average number of shares used to
  compute earnings per common share                     10,002     9,867

Effect of unexercised stock options                         39        70
                                                       -------   -------
Average number of shares used to 
  compute earnings per common share
  assuming full dilution                                10,041     9,937
                                                       =======   =======
Earnings per common share
  assuming full dilution                               $   .85   $  1.23
                                                       =======   =======

- ------------------
<F1>
(a)  This calculation is submitted in accordance with Regulation S-K Item 601 (b) (11)
although it is not required by APB Opinion No. 15 because it results in dilution of less than
3%.
</TABLE>
                                   E - 1
                               Page 12 of 12

<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION FROM FORM 10-Q FOR THE
QUARTER ENDED MARCH 31, 1997 FOR CHEMED CORPORATION AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000019584
<NAME> CHEMED CORPORATION
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                          17,797
<SECURITIES>                                         0
<RECEIVABLES>                                   82,690
<ALLOWANCES>                                   (2,971)
<INVENTORY>                                     51,429
<CURRENT-ASSETS>                               199,312
<PP&E>                                         143,544
<DEPRECIATION>                                (59,360)
<TOTAL-ASSETS>                                 548,635
<CURRENT-LIABILITIES>                          123,929
<BONDS>                                        158,092
                                0
                                          0
<COMMON>                                        12,858
<OTHER-SE>                                     200,078
<TOTAL-LIABILITY-AND-EQUITY>                   548,635
<SALES>                                         94,932
<TOTAL-REVENUES>                               168,552
<CGS>                                           64,311
<TOTAL-COSTS>                                  109,415
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   183
<INTEREST-EXPENSE>                               2,756
<INCOME-PRETAX>                                 13,926
<INCOME-TAX>                                     5,333
<INCOME-CONTINUING>                              8,487
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     8,487
<EPS-PRIMARY>                                      .85
<EPS-DILUTED>                                      .85
        

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission